COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-directed, TOPO1-inhibitor antibody-drug conjugate (ADC), for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior treatment with a platinum-containing re
Related Questions
What is the expected timeline for further clinical milestones and potential FDA approval following the Breakthrough Therapy Designation?
How will the Breakthrough Therapy Designation impact Genmab's valuation and stock price in the short term?
What competitive landscape does Rina‑S face in endometrial cancer and how might its efficacy compare to existing therapies?